CD34 and acute myeloid leukemia: Recently, SET expression studies in AML cell lines and CD34+ progenitors from healthy individuals and AML patients revealed that it was significantly increased in the cell lines tested as well as in primary patient samples harboring FLT3-ITD, NRASQ61L, and JAK3A572V genetic lesions (54).